|
|
|
 |
|
|
For more than a century, Abbott Laboratories
has been working to advance health care for people around the world. Founded by
a young Chicago physician, Dr. Wallace Calvin Abbott, in 1888, Abbott
Laboratories has evolved into a diversified health care company that discovers,
develops, manufactures and markets innovative products and services that span
the continuum of care - from prevention and diagnosis to treatment and cure.
Headquartered in north suburban Chicago, Abbott helps people around the world
in the more than 130 countries.
Building leadership and combining strengths in the areas of pharmaceuticals,
nutritionals, and diagnostics has enabled Abbott to provide total, integrated
solutions across the health care spectrum for some of the world’s most
prevalent medical conditions, including AIDS, cancer and diabetes. We focus on
advancing medical science and the practice of health care with expertise in the
therapeutic areas of diabetes, pain management, respiratory infections,
HIV/AIDS, men and women’s health, pediatrics and animal health.
|
|
is a leading provider of software for computation, simulation, and the
management and mining of scientific data used by biologists, chemists and
materials scientists, including nanotechnology researchers for product design
as well as drug discovery and development. Accelrys technology and services are
designed to meet the needs of today's leading research organizations.
|
|
|
is engaged in the discovery of
drug leads through the high-speed screening of diverse chemical libraries
designed by computational methods and generated by combinatorial chemistry.
Alanex utilizes proprietary software to design either broad or highly targeted
combinatorial libraries of molecules that can readily be synthesized in large
numbers. Alanex is presently conducting research projects aimed at discovery of
drugs for such therapeutic indications as pain, diabetes, obesity, anxiety, and
certain malignant tumors.
|
|
Ångstrom Pharmaceuticals, Inc. is a venture-backed
pharmaceutical company. Ångstrom’s proprietary products target a
clearly-defined pathway, the Urokinase Plasminogen Activation System (PA),
which has repeatedly been shown in scientific literature to be directly
involved in proliferative diseases, such as cancer and wet age-related macular
degeneration (ARMD). The Company’s lead product, Å6, is currently in a Phase 2
clinical trial for ovarian cancer. Ångstrom is headquartered in San Diego,
California.
|
|
As a member of the Chugai-Roche Group, Chugai Pharma USA LLC (CPUSA), founded
in 1995 in San Diego, CA and currently based in Bedminster, NJ, is committed to
the timely development and commercialization of safe and effective drugs for
the North American market place. For more than 70 years our parent company,
Chugai Pharmaceutical Co. Ltd., has provided high quality, safe and effective
drugs to the Japanese & global market place, a heritage that will be
continued in North America by CPUSA. As a result of our alliance with F.
Hoffmann-La Roche Ltd. in 2002, CPUSA enjoys the resources of a large global
conglomerate while preserving the focus and agility of a small local company.
CPUSA maintains the same therapeutic focuses as our parent, currently working
mainly in the areas of treatments for cardiovascular disease, cancer, metabolic
disease and diseases involving inflammation. We are a company of collaborative,
committed, talented and experienced people with an unwavering dedication to
quality and the highest environmental and ethical standards. We all take great
pride in bringing new medicines to market for the benefit of those in need.
|
|
|
The core technology of CMS is electro-chemical
detection. CMS has for a number of years been developing a low cost and easy to
use instrument and consumable as well as developing assays to enable this
technology to be used in the field of complex genetic diagnostics testing.
|
|
is a leading provider of drug discovery tools and services to the
biopharmaceutical industry. Deltagen offers a suite of programs designed to
enhance the efficiency of drug discovery including access to biological models
as well as both small-molecule and secreted protein drug targets. In addition,
Deltagen offers extensive target validation data in the areas of immunology and
metabolic diseases. Deltagen's products and programs have been validated by
customers and partners such as Eli Lilly & Co., GlaxoSmithKline, Merck
& Co., Millennium Pharmaceuticals and Pfizer.
|
|
Founded in 1970, the Friedrich Miescher
Institute is devoted to fundamental biomedi-
cal research. We employ new technologies
to explore basic molecular mechanisms
of cells and organisms in health and disease.
Our current research focuses on the fields
of epigenetics, growth control and neurobio-
logy. The FMI is an internationally recognised
research centre that has initiated key devel-
opments in molecular biology over the years.
We also provide young scientists from all
over the world with an opportunity to partici-
pate in scientific research. As a lively
educational establishment we have trained
hundreds of young scientists at the post-
graduate and postdoctoral levels. The FMI
is supported by the Novartis Research
Foundation as well as by grants from national
and international agencies. We have a total
staff of 250. In addition to the 22 research
group leaders and a core of technicians and
support staff, we are home to 90 PhD
students and 75 postdoctoral fellows from
almost 40 different countries. Our day-to-day
working language is English. Basel is a major
centre for research in biology, with out-
standing academic institutions and leading
life science companies. The city is also rich in
culture, with a unique cosmopolitan flare.
|
|
is a leading drug discovery and development company, focused exclusively on the
therapeutic target, RNA. Founded in 1989, Isis' mission is to develop products
from its RNA-based technologies, such as antisense. Very little was known about
antisense when the Company was first established, but its founders envisioned
an opportunity to revolutionize the pharmaceutical industry with a more
efficient and targeted means of drug discovery. Since then, Isis scientists
have made tremendous progress advancing the science of antisense, unveiling
capabilities that have far exceeded their expectations.
|
|
|
is engaged in the discovery, development, manufacture, and commercialization of
products to treat serious and life-threatening illnesses. NeXstar maintains
additional research, development, and manufacturing facilities in San Dimas,
CA, and marketing subsidiaries worldwide.
|
|
is the leading worldwide
developer of integrated molecular design software and a premier partner for
collaborative research services. The company aims to accelerate the drug
discovery process of its strategic partners and customers by offering: proven,
leading-edge software, custom software applications - collaborative research
services and an innovative network of academic research groups. The company's
focus is on the effective delivery and integration of bioinformatics, molecular
modeling and cheminformatics throughout the drug discovery process, this
integration enables collaboration and communication among scientists both
enterprise-wide and around the world. The company's unique collaborative
research services employ the expertise of a preeminent academic network to
provide innovation in software applications and drug design direct to Oxford
Molecular's partners.
|
|
, a
wholly owned subsidiary of Accelrys, Inc., designs, develops, and markets data
analysis and mining software to the pharmaceutical and biotechnology sectors.
The company provides the best possible systems for streamlining the processing
of the growing sources of diverse data types in today's life science research
environment.
|
|
is a clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel small molecule therapeutics for
oncology and other unmet medical needs. We have built our product candidate
portfolio through internal discovery and the in-licensing of novel cancer
therapeutics. We are advancing our product candidates through in-house research
and development efforts and strategic collaborations with leading
pharmaceutical and biopharmaceutical companies. We believe the quality and
breadth of our product candidate pipeline, platform technology, strategic
collaborations and scientific team will enable us to become a fully integrated
biopharmaceutical company with a diversified portfolio of novel therapeutics
for major diseases.
|
|
